Chemical Business Newsbase articles from April 2010

Chemical Business Newsbase archives from April 2010

Manufacturer of controlled substances; notice of application (Lonza Riverside).
April 30, 2010... Lonza Riverside, 900 River Road, Conshohocken, PA, USA, made application by renewal to the US Drug Enforcement Administration (DEA) on 16 Mar 2010 to be registered as a bulk manufacturer of the basic classes of controlled substances listed in...

Importer of controlled substances; notice of application (Penick Corp).
April 30, 2010... Penick Corp, 33 Industrial Park Road, Pennsville, NJ, USA, made application by renewal to the US Drug Enforcement Administration (DEA) on 15 Mar 2010 for registration as an importer of the basic classes of controlled substances listed in...

Garlic oil and capsaicin; registration review proposed decisions; notice of availability.
April 30, 2010... This notice, issued by the US Environmental Protection Agency (EPA), announces the availability of the agency's proposed registration review decisions for the pesticides garlic oil and capsaicin and opens a public comment period on the proposed...

Thanks to new Plexiglas Resist AAA multi-skin sheets!
April 30, 2010... Evonik Industries AG is offering a new multi-skin sheet called Plexiglas Resist AAA. This high-quality, next-generation multi-skin sheet features a nanotech-based anti-algae design. This special coating takes advantage of the sun's UV radiation...

Ferro and Heraeus close transaction.
April 30, 2010... Ferro Corp announced on 30 Apr 2010 that it closed its transaction with Heraeus of Hanau, Germany. The two companies have acquired from each other certain business lines concerning decoration materials for ceramic and glass products. Terms of...

New base of operation for the expanding South American market; decision to establish local subsidiary in Brazil; opening in Sao Paulo, Brazil targeted for 2010.
April 30, 2010... Kuraray Co Ltd announced on 30 Apr 2010 that it will accelerate market development in South America and has decided to establish a local subsidiary to accelerate core business development in emerging markets under the GS-Twins medium-term action...

Establishment of new jv for precursor production.
April 30, 2010... Mitsubishi Rayon Co Ltd and SGL Technologies GmbH have established a jv, MRC-SGL Precursor Co Ltd (MSP) for production and sales of precursor. MRC and SGL have established MSP to supply the precursor securely for SGL Automotive Carbon Fibers LLC...

Tessenderlo 1Q 2010: Key figures.
April 30, 2010... Tessenderlo Group's revenues for 1Q 2010 were EUR 567.3 M (1Q 2009: EUR 545.3 M). REBITDA rose to EUR 32.5 M (1Q 2009: EUR 19.7 M) and REBIT amounted to EUR 4.2 M (1Q 2009: -EUR 6.4 M). The loss for 1Q 2010 totalled -EUR 5.1 M (1Q 2009: -EUR 6.2...

Tessenderlo 1Q 2010: Inorganics results.
April 30, 2010... Tessenderlo Group's revenues for 1Q 2010 were EUR 567.3 M (1Q 2009: EUR 545.3 M). The Group's Inorganics operating segment reported a 1Q 2010 revenue of EUR 89.0 M (1Q 2009: EUR 86.5 M). REBITDA for Inorganics was negative, at -EUR 0.2 M (1Q...

Tessenderlo 1Q 2010: PVC / Chlor-alkali results.
April 30, 2010... Tessenderlo Group's revenues for 1Q 2010 were EUR 567.3 M (1Q 2009: EUR 545.3 M), and of this, the Group's PVC / Chlor-alkali operating segment accounted for EUR 118.2 M (1Q 2009: 125.7 EUR M). REBITDA for the segment was EUR 5.1 M (1Q 2009: EUR...

Tessenderlo 1Q 2010: Gelatin and Natural Derivatives results.
April 30, 2010... Tessenderlo Group's revenues for 1Q 2010 were EUR 567.3 M (1Q 2009: EUR 545.3 M), and of this, the Group's Gelatin and Natural Derivatives operating segment accounted for EUR 95.3 M (1Q 2009: EUR 88.4 M). The segment's REBITDA totalled EUR 15.2...

Tessenderlo 1Q 2010: Tessenderlo Kerley's results.
April 30, 2010... Tessenderlo Group's revenues for 1Q 2010 were EUR 567.3 M (1Q 2009: EUR 545.3 M), of which Tessenderlo Kerley accounted for EUR 54.5 M (1Q 2009: EUR 39.0 M). Tessenderlo Kerley's REBITDA amounted to EUR 11.6 M (1Q 2009: EUR 5.9 M) and REBIT...

Tessenderlo 1Q 2010: Plastic Pipe Systems and Profiles results.
April 30, 2010... Tessenderlo Group's revenues for 1Q 2010 were EUR 567.3 M (1Q 2009: EUR 545.3 M), of which the Group's Plastic Pipe Systems and Profiles operating segment accounted for EUR 126.9 M (1Q 2009: EUR 128.7 M). The segment reported a REBITDA of EUR...

Tessenderlo 1Q 2010: Results from Other Businesses (Pharmaceutical Intermediates, Organic Chlorine Derivatives and Compounds).
April 30, 2010... Tessenderlo Group's revenues for 1Q 2010 were EUR 567.3 M (1Q 2009: EUR 545.3 M), of which the Group's 'Other Businesses' (Pharmaceutical Intermediates, Organic Chlorine Derivatives and Compounds) accounted for EUR 83.3 M (1Q 2009: EUR 77.1 M)....

Chelsea Therapeutics reports 1Q 2010 results.(Financial report)
April 30, 2010... Chelsea Therapeutics International Ltd (Chelsea) reported financial results for 1Q ended Mar 2010 and presented a quarterly update on the company's development progress. Chelsea reported a net loss for 1Q 2010 of $6.2 M or $0.18/share (net loss...

iCo Therapeutics Inc announces 2009 financial results.(Financial report)
April 30, 2010... iCo Therapeutics Inc reported financial results for the year ended Dec 2009. The company incurred a net and comprehensive loss of C$ 2,308,490 for 2009 (net and comprehensive loss of C$ 2,742,374 in 2008). Research and development expenses were...

Cytokinetics Inc reports 1Q 2010 financial results.(Financial report)
April 30, 2010... Cytokinetics Inc reported revenues from research and development collaborations of $600,000 for 1Q 2010. The net loss for 1Q 2010 was $12.2 M or $0.20/basic and diluted share (net loss of $10.7 M or $0.21/basic and diluted share in 1Q 2009)....

Suven Life Sciences Ltd spends 26% of revenue on R&D for the year ended Mar 2010.(Financial report)
April 30, 2010... Suven Life Sciences Ltd announced its audited financial results for 4Q as well as year ended Mar 2010. Financial Highlights for 4Q 2009-2010: growth in revenue -8.15% (Rup 364 M vs Rup 396 M), growth in PAT 352.36% (Rup 15.80 M vs Rup 3.5 M),...

China Pediatric reports reverse merger, 2009 results.(Financial report)
April 30, 2010... China Pediatric Pharmaceuticals Inc, which completed its reverse merger in Oct 2009, said its revenues rose 14% in 2009 to $16.7 M, though net income declined slightly to $2.5 M. The company ended its fiscal year with $900,000 in cash. Its only...

Taro provides preliminary 2009 full year results.(Financial report)
April 30, 2010... Taro Pharmaceutical Industries Ltd (Taro) provided preliminary, unaudited and unreviewed information on its financial performance for year ended Dec 2009. For 2009, Taro estimates net sales of $360.5 M (estimated net sales of $336.7 M in 2008)....

Allergan reports 1Q 2010 operating results.(Financial report)
April 30, 2010... Allergan Inc announced operating results for 1Q ended Mar 2010. Allergan also announced that its Board of Directors has declared a 1Q 2010 dividend of $0.05/share, payable on 8 Jun 2010 to stockholders of record on 18 May 2010. For 1Q 2010:...

Ziopharm reports 1Q 2010 financial results.(Financial report)
April 30, 2010... Ziopharm Oncology Inc (Ziopharm) reported its financial results for 1Q ended Mar 2010 and updated the company's continued progress with its clinical programmes. The net loss from operations for 1Q 2010 was $4.6 M, or $0.11/share (net loss from...

MannKind Corp reports 1Q 2010 financial results.(Financial report)
April 30, 2010... MannKind Corp reported financial results for the 1Q ended Mar 2010. Research and development (R&D) expenses were $30.5 M for 1Q 2010 ($42.9 M in 1Q 2009). This 29% decrease in R&D expense was primarily due to reduced costs associated...

BioScrip Inc reports 1Q 2010 results.(Financial report)
April 30, 2010... BioScrip Inc announced a 1Q 2010 net loss of $7.2 M, or $0.18/share on revenues of $335.1 M (net income of $3.3 M, or $0.08/share, on revenues of $325.7 M in 1Q 2009). The net loss includes one-time transaction expenses of $7.3 M ($5.5 M, net of...

Endo Pharmaceuticals reports strong revenue growth and 1Q 2010 financial results.(Financial report)
April 30, 2010... Endo Pharmaceuticals reported financial results for 1Q ended Mar 2010. Total revenues during 1Q 2010 increased 9% to $364 M ($335 M in 1Q 2009). Net income for 1Q 2010 was $60 M (net income of $39 M in 1Q 2009). As detailed in the supplemental...

Ista Pharmaceuticals reports 1Q 2010 financial results.(Financial report)
April 30, 2010... Ista Pharmaceuticals Inc (Ista) reported financial results for 1Q ended Mar 2010. The 1Q 2010 net revenues were $28.3 M, an increase of 39%. Net income for 1Q 2010 was $500,000, or $0.01/share (net loss of $19.6 M, or $0.59/share, for 1Q 2009)....

Vitro reports 1Q 2010 increase of 1.2% in sales and 5% decrease in EBITDA.
April 30, 2010... Vitro SAB de CV announced 1Q 2010 unaudited results. Net sales for 1Q 2010 were $424 M (+1.2% over $419 M in 1Q 2009). Sales from glass containers segment stood at $214 M (+1.4% over $211 M in 1Q 2009). The flat glass segment recorded sales of...

The Laclede Group announces results for 2Q 2010.(Financial report)
April 30, 2010... The Laclede Group Inc announced net income for its 2Q ended Mar 2010 totalling $28 M, or $1.26 diluted earnings/share (net income of $30.8 M, or $1.39/share, for 2Q ended Mar 2009). On a non-GAAP basis, The Laclede Group reported 2Q 2009-2010...

China Sunergy announces financial results for 1Q 2010.(Financial report)
April 30, 2010... China Sunergy Co Ltd announced its financial results for 1Q ended Mar 2010. Revenues were $104.3 M, representing a 181.9% increase. Revenues generated from solar cell sales were $91.7 M, representing a 166.6% increase. GAAP net income was $7.1 M...

Europlasma: 2009 full-year earnings; significant investments for strong and profitable growth in 2010.(Financial report)
April 30, 2010... At the Board meeting held on 29 Apr 2010, Europlasma's directors approved the financial statements for 2009. Europlasma, the French Group specialized in clean technologies and renewable energy production, is releasing its full-year earnings for...

Tessenderlo Group 1Q 2010.
April 30, 2010... For its 1Q 2010, Tessenderlo group has reported revenue of EUR 567.3 M (+4% on its 1Q 200(), REBITDA of EUR 32.5 M (+65.0%), REBIT of EUR 4.2 M (returns to positive), and a net loss of EUR 5.1 M. The company received EUR 4.5 M from the sale of...

DSM 1Q 2010 very strong.
April 30, 2010... For its 1Q 2010, DSM has reported operating profit (from continuing operations) of EUR 196 M (EUR 44 M for 1Q 2009 and EUR 149 M for 4Q 2009). Life Sciences and Materials Sciences made a solid contribution. DSM Agro and DSM Melamine were sold....

Tops in clinical trials.
April 30, 2010... According to a recent survey, Belgium has the highest number of pharmaceutical drugs in development per capita in Europe and over 40% of private investment is in the pharmaceutical sector. Belgian law provides for extremely short approval times...

New plant for Echo.
April 30, 2010... Floor coverings producer Echo has opened a new EUR 20 M plant at Genk Zuid. The Plant has a capacity of 730,000 sq m/y flooring elements and concrete and will have 37 employees. The plant is close to the Albert Canal and materials will be...

Reichhold announces price increase on all products for European Composites Industry.
April 30, 2010... Reichhold announces a 100 EUR/MT price increase effective for all orders shipped on or after 17 May 2010 in Europe. Raw material prices have continued to increase primarily due to tight availability of feedstock and strong demand in Asian...

Phoenix and MiaSole enter solar thin-film agreement.
April 30, 2010... A copper-indium-gallium-selenide (CIGS) thin-film solar PV module supply arrangement has been agreed between US module manufacturer MiaSole and Phoenix Solar AG. The arrangement covers the period 2Q 2010-2013, and MiaSole can recover the modules...

FRV and BP Solar build 37 MW of solar PV in Italy.
April 30, 2010... In Italy, solar PV projects with a total generating capacity of 37.1 MW are to be established by BP Solar and Fotowatio Renewable Ventures (FRV). FRV will spend EUR 125 M on the facilities, and will own and operate them. BP will construct the...

Renewable energy up 250% in 1Q 2010.
April 30, 2010... In the UK EIC's Monitor quarterly report it is stated that, in 1Q 2010, new renewable energy projects implemented around the world had a total value of $224 bn, 250% more than for 1Q 2009. During 1Q 2009, 25 GW of off-shore wind power schemes...

UK pesticides register new approval (Apr 2010): Coragen.
April 30, 2010... On 30 Apr 2010, the UK Pesticides Safety Directorate (PSD) announced the provisional approval (20101387) of Coragen (MAPP No 14930). The approval document is available, as a 6-page Word document, on the website. Formulation type: suspension...

MEPs return to Brussels on 3 May 2010 for two days of committee meetings: industrial emissions.
April 30, 2010... On 4 May 2010, the environment committee of the European Parliament was due to adopt, at the second reading stage, a directive on industrial emissions. As part of the debate on the previous day, Martin Callanan, the Conservative MEP for the...

PTTAR studying jet biofuel potential.
April 30, 2010... PTT Aromatics and Refining Plc (PTTAR) announced that a plan for the production of aviation biofuel is in the offing to cater to the growing need of a green fuel for the aviation industry. The company is in talks with the Energy Ministry for a...

UltraTech buys Dubai company ETA Star Cement: 4Q net down 26% on lower realisations.
April 30, 2010... UltraTech Cement, belonging to the Aditya Birla group, has reported 26% lower net profit at Rup 229 crores on revenues of Rup 1909 crores for 4Q ended Mar 2010 (net profit of Rup 309 crores on revenues of Rup 1860 crores in 4Q ended Mar 2009)....

MRF 2Q ended Mar 2010 net profit up 40%.(Financial report)
April 30, 2010... MRF Ltd has recorded a 40% increase in profit-after-tax at Rup 95.82 crores on sales of Rup 1767.58 crores for 2Q ended Mar 2010 (profit-after-tax of Rup 68.69 crores on sales of Rup 1404.72 crores in 2Q ended Mar 2009). (1 crore=10 M, 1...

Exide reaches pact with workers.
April 30, 2010... Battery manufacturer Exide Industries has reached an agreement with the workers who were on a 'go slow' strike at its Bawal plant in Haryana. Consequently normal production will resume soon. The 'go slow' strike resulted in a 50% production loss...

Hind National Glass forms joint venture with Belgium company.
April 30, 2010... Hindustan National Glass & Industries Ltd has formed a 50:50 joint venture with the Belgium-based OMCO International NV. Initially, the joint venture will set up a glass mould manufacturing facility at Puducherry at an investment of Rup 35...

Vedanta in pact with minerals institute.
April 30, 2010... Vedanta Resources Ltd has signed a Memorandum of Understanding (MoU) with the Institute of Mineral and Materials Technology to develop technology to recover materials from waste generated by alumina refinery. Vedanta has provided Rup 1 crore to...

Oralium launches aluminium building sheets.
April 30, 2010... The Kochi-based Oralium has launched a premium brand of aluminium products, including building sheets, doors and windows, in South India. The company is offering painted building sheets to provide aesthetic appeal.

Gulbarga set to become cement manufacturing hub.
April 30, 2010... Gulbarga district of Karnataka State is set to become a cement manufacturing hub, as ten cement firms including Zuari, Vicat Sagar, Shree Cement, Reliance, India Cements Ltd and Chettinad have been given clearances to set up plants in the...

Orchid, Forest Lab settle litigation.
April 30, 2010... Orchid Chemicals & Pharmaceuticals Ltd has settled the patent litigation with Forest Laboratories related to the generic version of Nameda of Forest Laboratories. Nameda is used to treat Alzheimer's disease.

Biocon net profit up 3-fold at Rup 81 crores: Robust growth in pharmaceuticals and contract research business cited as main reasons.
April 30, 2010... The Bangalore-based biotechnology major Biocon Ltd has garnered a net profit of Rup 81 crores, a three-fold increase, on 37% higher revenues at Rup 666 crores for 4Q ended Mar 2010. The improved performance is attributed to increase in pharma...

HUL merges Bon with itself.
April 30, 2010... Hindustan Unilever Ltd (HUL) has merged its subsidiary Bon Ltd with itself following the approval granted by the Bombay High Court.

RSWM Ltd: Results for 4Q 2009-2010.
April 30, 2010... RSWM Ltd has reported a profit of Rup 2481 lakhs on net sales/income from operations of Rup 40,681 lakhs for 4Q ended Mar 2010 (profit of Rup 84 lakhs on net sales/income from operations of Rup 35,331 lakhs in 4Q ended Mar 2009). During 4Q...

JCT Ltd: Results for 4Q 2009-2010.
April 30, 2010... JCT Ltd has incurred a net loss of Rup 1926 lakhs on net sales/income from operations of Rup 15,207 lakhs for 4Q ended Mar 2010 (net loss of Rup 2046 lakhs on net sales/income from operations of Rup 15,096 lakhs in 4Q ended Mar 2009). During 4Q...

Cadila Healthcare: Results for 4Q 2009-2010.
April 30, 2010... Pharma firm Cadila Healthcare Ltd has posted a net profit of Rup 11,876 lakhs on net sales of Rup 81,589 lakhs, on a consolidated basis, for 4Q ended Mar 2010 (net profit of Rup 5800 lakhs on net sales of Rup 70,255 lakhs in 4Q ended Mar 2009)....

Dhampur Sugar Mills: Results for 4Q 2009-2010.
April 30, 2010... Dhampur Sugar Mills Ltd has recorded a net profit of Rup 1238.58 lakhs on net sales/income from operations of Rup 29,013.51 lakhs for 4Q ended Mar 2010 (net profit of Rup 1752.48 lakhs on net sales/income from operations of Rup 10,932.97 lakhs...

Lighter and more stable: vehicle builders planning the carbon age.
April 30, 2010... German automotive companies are getting a move on in the rediscovery of the car. To this end, the top manufacturers are engaging in alliances for bodies made from new materials. Following in the footsteps of BMW, Daimler has now found a partner...

Rabat CR to be taken over by IN Group.
April 30, 2010... Rabat CR (Prague, Czech Republic), construction materials distributor, will be taken over by the group, IN Group (Slovakia). IN Group asked the Antimonopoly Office of the Czech Republic for agreement to the transaction in Apr 2010. IN Group will...

CEZ gets permission to modernize the Prunerov power plant.
April 30, 2010... CEZ (Prague, Czech Republic), semi-state power group, has got permission to modernize its power plant Prunerov worth CEK 25 bn from the Ministry of Environment of the Czech Republic. But CEZ is still not sure if it is allowed to modernize this...

BP's share price plunges as clean-up costs mount.
April 30, 2010... BP saw nearly GBP 8 bn wiped off its value yesterday after US President Barack Obama said the company must pay the clean-up costs of the giant oil spill in the Gulf of Mexico. The oil major's share price plunged another 6% as the US military...

Oil spill in Gulf of Mexico 'could be worse than Exxon Valdez disaster': BP struggles to stop crude pouring from well a mile under the sea as growing slick menaces US coastline.
April 30, 2010... The first coating of oil from a growing spill in the Gulf of Mexico was expected to reach the US shoreline on 29 Apr 2010, despite frantic efforts by the US and BP to halt its drift and avert the threat of an environmental calamity not seen...

Market Report: Technip's success hits Wellstream's shares.
April 30, 2010... Shares attempted a comeback as nerves about the southern Europe's debt woes eased last night, but Wellstream was held back after losing out on a major contract in Brazil. The oilfield services group, which specialises in flexible pipes and is...

Investment Column: BG Group.(Column)
April 30, 2010... BG Group announced 1Q 2010 results on 29 Apr 2010 showing profits of $960 M (GBP 628 M), a 5% fall on 1Q 2009, blamed on depressed gas prices. But elsewhere the results were more positive, with underlying profits up by an expectations-beating...

US approves new treatment for advanced prostate cancer.
April 30, 2010... US regulators have approved a ground-breaking treatment for advanced prostate cancer that uses a patient's own immune system to fight the disease, officials said on Thu 29 Apr 2010. The US Food and Drug Administration (FDA) said the treatment...

TransCanada declares quarterly dividends, board approves dividend of $0.40 per common share.
April 30, 2010... On 30 Apr 2010, TransCanada Corp announced that the Board of Directors (Board) of TransCanada declared a quarterly dividend of $0.40 per common share for the quarter ending 30 Jun 2010 on the Company's outstanding common shares. The common share...

Brazil 1Q industrial chemical output up 15.64% yoy.
April 30, 2010... Brazilian Chemical Industry Association reported 15.64% hike in Brazilian Chemical Industrial output for 1Q 2010 compared to 1Q 2009. However, the domestic sales increased by 16.39%. During the 1Q 2010, the chemical industries average progress...

Gene expression test reduces need for invasive heart muscle biopsy.
April 30, 2010... Monitoring rejection in heart transplantation patients with a simple blood test co-developed by NY-Presbyterian Hospital/Columbia University Medical Center physician-scientist Dr Mario Deng in 2005 can safely reduce their need for invasive...

Team studies T cell activation with nanoparticles.
April 30, 2010... A University of Alberta-led research team has taken a major step forward in understanding how T cells are activated in the course of an immune response by combining nanotechnology and cell biology. T cells are the all important trigger that...

FDA provides consumer advice following recall of products for infants and children.
April 30, 2010... Working in consultation with the US Food and Drug Administration (FDA), McNeil Consumer Healthcare is implementing a voluntary recall of infant and children's liquid products due to manufacturing deficiencies which may affect quality, purity or...

FDA approves Chagas disease screening test for blood, tissue and organ donors: Another test to detect Trypanosoma cruzi infection.
April 30, 2010... On 30 Apr 2010, the US Food and Drug Administration approved a second test to screen blood, tissue and organ donors for a blood-borne parasite, Trypanosoma cruzi (T. cruzi) that causes Chagas disease, a serious and potentially fatal parasitic...

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 Jan 2010 to 28 Feb 2010.
April 30, 2010... The following decisions are taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council on marketing authorizations in...

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 Jan 2010 to 28 Feb 2010.
April 30, 2010... The European Union has accepted Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): accepted ; Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): accepted; and Modification of a...

Key information regarding member states of the European Union and their pharmaceutical markets.
April 30, 2010... A detailed table lists the pharmaceuticals markets for member states of the EU in 2007 as follows: Belgium EUR 3933 M; Bulgaria EUR 542 M; Denmark EUR 1860 M; Germany EUR 25,241 M; Estonia EUR 137 M; Finland EUR 1848 M; France 25,501 M; Greece...

Figures and facts regarding the European pharmaceuticals market.(Industry overview)
April 30, 2010... According to the European Umbrella Association for the Pharmaceuticals Industry (EFPIA), Europe accounted for around 31% of the global pharmaceuticals turnover (at manufacturer's prices) in 2008. The market in the US and Canada generated 45.9%...

Poland: Adamed acquires Polfa Pabianice.
April 30, 2010... The Polish pharmaceuticals manufacturer Adamed acquired 85% of shares in Polfa Pabianice (PP) from the state-owned Polski Holding Farmaceutyczny (PHF) on 4 Feb 2010. Adamed already owns a wide portfolio in 22 foreign markets and aims to further...

AstraZeneca and Rigel establish licence agreement for fostamatinib.
April 30, 2010... US company AstraZeneca and Rigel Pharmaceuticals established an exclusive licence agreement in Feb 2010 for the global development and marketing of fostamatinib disodium (R788) for the treatment of rheumatoid arthritis as well as for other...

Clinical trials for mildronate to treat angina.
April 30, 2010... The pharmaceuticals company Grindeks in Latvia reported the successful completion of an important research project for its pharmaceutical mildronate in Feb 2010. The randomised, double blind, placebo-controlled study in 37 centres in Latvia,...

Roche publishes research results for Avastin: good and not so good news.
April 30, 2010... Roche Group published the most important results of a global phase III study on 23 Feb 2010 regarding the administration of the pharmaceutical Avastin (bevacizumab) in combination with Xeloda (capecitabin) or chemotherapy with Fluorouracil and...

Germany: 37 pharmaceuticals with new active ingredients in 2009.
April 30, 2010... According to the Annual Report 2009 by the German Association of Researching Pharmaceuticals companies (VFA), 37 pharmaceuticals with new active ingredients entered the Germany market in 2009. These drugs target following diseases: cancer (7 new...

Italy: Glaxo announces closure of research centre.
April 30, 2010... The Italian Pharmaceuticals Association Farmindustria announced on 5 Feb 2010 that the pharmaceuticals company GlaxoSmithKline plans to close down its research centre in Verona in Italy.

Activa Pharma expands OTC distribution in South Eastern Europe.
April 30, 2010... Activa Pharma, a multinational distribution partner for the launch, circulation and marketing of over-the-counter (OTC) drugs and beauty products in Southern Europe, expanded its distribution network (which consists of 35,000 pharmacies and...

Romania: Antibiotice fights the crisis with exports.
April 30, 2010... The Romanian pharmaceuticals company Antibiotice continued its strategic focus on exports in 2009. Since 2006 sales in foreign markets almost doubled (EUR 9.7 M). The company achieved a 27% rise in turnover in 2009. Antibiotice's largest...

Switzerland: higher illegal imports of pharmaceuticals.
April 30, 2010... According to the Swiss Healthcare Institute Swissmedic, Switzerland recorded a 68% rise in illegal imports of pharmaceuticals in 2009 but the actual figure is expected to be much higher. Pharmaceutical packages confiscated by Swiss customs...

FDA approves Botox for spasms.
April 30, 2010... The US Food and Drug Administration (FDA) approved Botox (onabotulinumtoxin A) for spasms in the bending muscles in the elbows, wrists and fingers in adults. Spasticity often occurs after a stroke, skull-brain injuries or in advanced multiple...

FDA approves VPRIV for Gaucher's disease.
April 30, 2010... The US Food and Drug Administration (FDA) approved VPRIV (Velaglucerase alfa), an enzyme replacement therapy (ERT) which is based on a human cell line, for the long-term treatment of Gaucher's disease (type 1) in paediatric and adult patients....